Clinical characteristic or laboratory test abnormality | ICU | Non-ICU | P | ||
---|---|---|---|---|---|
 | data | n | data | n |  |
Medical Condition (no. (%)) | 16 (53) | 30 | 7 (18) | 38 | 0.003# |
Cigarette index ≥ 400(no. (%)) | 5 (17) | 30 | 4 (10) | 38 | 0.458 |
BMI ≥ 24 (no. (%)) | 23(77) | 30 | 19(50) | 38 | 0.025# |
   BMI 24-27.9 | 10 (33) | 30 | 10 (32) | 38 | 0.528 |
   BMI ≥ 28 | 13 (43) | 30 | 9 (24) | 38 | 0.085 |
Median age | 41 (18-63) | 30 | 41 (18-66) | 38 | 0.990 |
Interval from onset of illness to initiation of antiviral therapy, in days | 7 (4-12) | 30 | 7 (2-15) | 38 | 0.551 |
Lymphcyto count (×109/L) | 0.58 (0.02-4.34) | 30 | 1.065 (0.31-2.48) | 38 | <0.0005** |
LDH (U/L) | 1097.5 (218-4340) | 30 | 688 (180-2250) | 37 | 0.005** |
CK (U/L) | 220 (23-4188) | 30 | 161 (20-2712) | 37 | 0.313 |
AST (U/L) | 66 (12-229) | 30 | 41.5 (13-339) | 38 | 0.107 |
ALT (U/L) | 45.5 (15-188) | 30 | 43.5 (11-204) | 38 | 0.537 |
Alb (g/L) | 28.95 (18-42) | 30 | 37 (9.6-51) | 38 | <0.0005** |
CRP (mg/mL) | 2.66 (0.25-29.7) | 27 | 1.23 (0.1-10.2) | 38 | 0.024** |
CD4 T cell count (/μL) | 232 (29-1892) | 28 | 651 (128-1607) | 36 | <0.0005** |
CD8 T cell count (/μL) | 166.5 (23-1109) | 28 | 406 (85-1113) | 36 | <0.0005** |
CD3 T cell count (/μL) | 465 (57-3046) | 28 | 1148.5 (216-2496) | 36 | <0.0005** |